Previous 10 | Next 10 |
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd., relate...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced details of its upcoming presentation of initial data from the ongoing Phase 1 dose escalat...
Oncorus (NASDAQ:ONCR) has filed for a mixed shelf offering of up to $200M. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Oncorus' focus is on viral immunotherapies. Its only clinical candidate is ONCR-177 as monotherapy and in combination with Ke...
Oncorus (NASDAQ:ONCR): Q3 GAAP EPS of -$0.65 misses by $0.01. Cash and cash equivalents as of September 30, 2021 of $145.6M Press Release For further details see: Oncorus EPS misses by $0.01
To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36 th Annual Meeting on November 12...
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced it will present initial data from its ongoing Phase 1 clinical trial of ONCR-177 at the ...
Oncorus (NASDAQ:ONCR): Q2 GAAP EPS of -$0.60 misses by $0.04. $159.9 million in cash and cash equivalents as of June 30, 2021. Press Release For further details see: Oncorus EPS misses by $0.04
Continues to progress Phase 1 clinical trial of ONCR-177, company’s lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q’21 Nominated company’s first intravenously (IV) administered Synthetic viral...
-- Former Merck executive brings extensive experience in corporate development, licensing and financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a cli...
Oncorus shares have been in steady decline since nearly doubling in value less than six months after the company's October 2020 IPO. Current trading price of $13 is slightly under the $15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ON...
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...